Metraipolis › archive › dc_63da267bebfb

Exploring patient preferences regarding the use of combination therapy with endothelin receptor antagonist (ERA) + phosphodiesterase-5 inhibitors (PDE5i) — Europe PMC PMID:41281767

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41281767
DOI: 10.1016/j.jhlto.2025.100410
License (as archived): solo-consultazione
Archived: 2026-11-09T07:12:36.354Z
SHA-256 of the archived text: 6fb68e8710a3bef840972923a084da89e057ef8b521c910c7ef50fab16ccfe9e
Stable URL of this page: https://metraipolis.com/documento/dc_63da267bebfb

How to cite

Exploring patient preferences regarding the use of combination therapy with endothelin receptor antagonist (ERA) + phosphodiesterase-5 inhibitors (PDE5i) — Europe PMC PMID:41281767 — Europe PMC (en), https://europepmc.org/article/MED/41281767 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_63da267bebfb (Metraipolis archive dc_63da267bebfb, sha256 6fb68e8710a3bef840972923a084da89e057ef8b521c910c7ef50fab16ccfe9e)

BibTeX

@misc{dc63da267bebfb,
  title = {Exploring patient preferences regarding the use of combination therapy with endothelin receptor antagonist (ERA) + phosphodiesterase-5 inhibitors (PDE5i) — Europe PMC PMID:41281767},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41281767},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_63da267bebfb; sha256 6fb68e8710a3bef840972923a084da89e057ef8b521c910c7ef50fab16ccfe9e},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41281767. Agents can read the archived copy with the MCP tool read_document.